Literature DB >> 17067196

Information created to evade reality (ICER): things we should not look to for answers.

Stephen Birch1, Amiram Gafni.   

Abstract

Cost-effectiveness analysis has been advocated in the health economics methods literature and adopted in a growing number of jurisdictions as an evidence base for decision makers charged with maximising health gains from available resources. This paper critically appraises the information generated by cost-effectiveness analysis, in particular the incremental cost-effectiveness ratio (ICER). It is shown that this ratio is used as comparative information on what are non-comparable options and hence evades the reality of the decision-maker's problem. The theoretical basis for the ICER approach is the simplification of theoretical assumptions that have no relevance to the decision maker's context. Although alternative, well established methods can be used for addressing the decision maker's problem, faced with the increasing evidence of the theoretical and empirical failures of the cost-effectiveness approach, some proponents of the approach now propose changing the research question to suit the approach as opposed to adopting a more appropriate method for the prevailing and continuing problem. As long as decision makers are concerned with making the best use of available healthcare resources, cost-effectiveness analysis and the ICER should not be where we look for answers.

Mesh:

Year:  2006        PMID: 17067196     DOI: 10.2165/00019053-200624110-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  33 in total

1.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.

Authors:  P P Sendi; A H Briggs
Journal:  Health Econ       Date:  2001-10       Impact factor: 3.046

3.  Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant.

Authors:  Jack Dowie
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

4.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

5.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 6.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

7.  Applications of cost-benefit analysis to health care. Departures from welfare economic theory.

Authors:  S Birch; C Donaldson
Journal:  J Health Econ       Date:  1987-09       Impact factor: 3.883

8.  Medicare and cost-effectiveness analysis.

Authors:  Peter J Neumann; Allison B Rosen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

9.  Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.

Authors:  Karl Claxton; Mark Sculpher; Anthony Culyer; Chris McCabe; Andrew Briggs; Ron Akehurst; Martin Buxton; John Brazier
Journal:  Health Econ       Date:  2006-01       Impact factor: 3.046

10.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

View more
  21 in total

Review 1.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Better analysis for better decisions: facing up to the challenges.

Authors:  Michael F Drummond; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Methods of economic evaluation for the German statutory healthcare system.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  How good is good enough? Standards in policy decisions to cover new health technologies.

Authors:  Mita Giacomini
Journal:  Healthc Policy       Date:  2007-11

6.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

Review 7.  Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.

Authors:  Samuel D Shillcutt; Damian G Walker; Catherine A Goodman; Anne J Mills
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

Review 9.  Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making.

Authors:  Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Recommendations for increasing the use of HIV/AIDS resource allocation models.

Authors:  Arielle Lasry; Anke Richter; Frithjof Lutscher
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.